
# **Investor Call** Q2 2022



> Plochingen, September 28, 2022 – public-side information only

• CEO – Dr. Hadi Saleh





# Investor Call – 2022 Q2 Financial Information Disclaimer

This document contains statements that constitute forward-looking statements. These statements appear in a number of places in this document and include statements regarding the intent, belief or current expectations of our customers, estimates regarding future growth in the different business lines and the global business, market share, financial results and other aspects of the activity and situation relating to the Company. The forward-looking statements in this document can be identified, in some instances, by the use of words such as "expects", "anticipates", "intends", "believes", "plan", "seek", "will", "project", and similar language or the negative thereof or by forward-looking nature of discussions of strategy, plans or intentions. Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and other important factors that could cause actual developments or results to differ materially from those expressed in our forward-looking statements. Analysts and investors are cautioned not to place undue reliance on those forward-looking statements which speak only as of the date of this presentation. CeramTec undertakes no obligation to release publicly the results of any revisions to these forward-looking statements which may be made to reflect events and circumstances after the date of this presentation, including, without limitation, changes in the Company's business strategy or to reflect the occurrence of unanticipated events. The financial information contained in this document has been prepared under IFRS. This financial information is unaudited and, therefore, subject to potential future modifications.



### **Investor Call Q2 2022** Overview of Q2 Performance




- Group Revenue Q2'22: EUR 190.5m +12.6% vs. PY
- Medical Markets\* Revenue Q2'22: EUR 98.8m +19.7% vs. PY. Continued strong growth in all medical end markets driven by strong implant business
- Industrial Markets\* Revenue Q2'22: EUR 91.8m +5.8% vs. PY. Ongoing recovery in business across nearly all end markets and regions
- Management-Adjusted EBITDA Q2'22: EUR 79.3m +8.7% vs. PY.
- Management-Adjusted EBITDA margin Q2'22 of 41.6%
- Following the new financing total net debt leverage ratio Q2'22 at 7.2x including EUR 23.4M of cash on hand at the end of Q2 2022

\* Historically, the performance of the Group was monitored based on a Business Unit / legal entity view. In this structure, Medical Products includes Orthopaedic and Dental implants only. All other products were allocated to the Industrial business. Since January 2022, we have been looking at the overall business from a target market perspective, that is split into Medical and Industrial markets and leads to the medical equipment products previously shown in the Industrial business sold to medical customers now being classified in the Medical Markets.




### Investor Call Q2 2022 Q2 2022 Performance


#### Revenue (EURm)




#### Net Capex (EURm)



#### Management Adjusted EBITDA (EURm)




#### Management Adjusted EBITDA – Net Capex (EURm)






### Investor Call Q2 2022 Medical and Industrial Markets – Revenue Trend



Industrial Markets (EURm)



#### Comments

- Q2'22 Medical Markets Revenue +19.7% vs. PY. On constant currency, revenue growth was +19.3% vs PY.
- Key drivers for the strong performance were growing demand from key customers in China and North America for implants based on solid market growth.
- Medical equipment is also seeing continued growth supported also by new product and customer wins.
- Good entry into Dental Market with customer wins and new product launches.

- Q2'22 Industrial Revenue +5.8% vs. PY. On constant currency, revenue growth was +2.1% vs PY.
- Recovery driven by continued good Order Income which already saw a positive trend and recovery of business after first wave of Covid-19 pandemic, affecting nearly all key markets. Mobility end markets with continued slower development due to supply chain issues at various customers.
- > Especially positive development in Asia and North America.



### Investor Call Q2 2022 Q2 2022 Management Financials

In EURm	Q2 2022	Q2 2021	Δ
Net Revenue	190.5	169.2	12.6%
Medical Markets	98.8	82.5	19.7%
Industrial Markets	91.8	86.8	5.8%
Gross Profit <sup>(1)</sup>	101.7	91.9	10.7%
as % of Revenue	53.4%	54.3%	-0.9
SG&A <sup>(1)</sup>	-22.6	-19.2	17.4%
as % of Revenue	-11.8%	-11.4%	
Other Inc./Exp. <sup>(1)</sup>	0.1	0.2	n/a
as % of Revenue	0.1%	0.1%	
Management Adj. EBITDA	79.3	72.9	8.7%
as % of Revenue	41.6%	43.1%	-1.5

(1) SG&A incl R&D; w/o Depreciation and Amortization and other extraordinary items Note: All figures in EURm at actual FX rates including normalization adjustments

- Q2'22 Revenue: Medical Markets increased by +19.7% vs. PY and Industrial Markets increased by +5.8% vs. PY, both businesses continue to benefit from the recovery of the markets from Covid-19 impact as well as new customer generation. Within Industrial markets the mobility end markt continues seeing slower growth due to worldwide supply chain issues.
- Q2'22 Gross margin: -0.9%pts behind PY, good volumes offset by inflation and energy cost effects with price increases which were put in place with a certain time lag to realize full impact.
- Q2'22 SG&A margin: decrease vs. PY by 0.4%pts partly driven by volume growth, selected initiatives to improve customer focus and some inflationary pressure, with ongoing cost control.
- Q2'22 Management Adj. EBITDA margin at 41.6% with -1.5%pts vs PY.



### Investor Call Q2 2022 YTD 2022 Management Financials

In EURm	YTD 2022	YTD 2021	Δ
Net Revenue	375.6	337.6	11.3%
Medical Markets	192.4	165.4	16.3%
Industrial Markets	183.4	172.4	6.3%
Gross Profit <sup>(1)</sup>	197.6	182.6	8.2%
as % of Revenue	52.6%	54.1%	-1.5
SG&A <sup>(1)</sup>	-45.0	-40.0	12.6%
as % of Revenue	-12.0%	-11.8%	
Other Inc./Exp. <sup>(1)</sup>	-0.3	0.8	n/a
as % of Revenue	-0.1%	0.2%	
Management Adj. EBITDA	152.2	143.4	6.2%
as % of Revenue	40.5%	42.5%	-1.9


(1) SG&A Incl R&D; w/o Depreciation and Amortization and other extraordinary items Note: All figures in EURm at actual FX rates including normalization adjustments

- Q2'22 Revenue: Medical Markets increased by +16.3% vs. PY and Industrial Markets increased by +6.3% vs. PY, both businesses continue to benefit from the recovery of the markets leading to good order book development. Within Industrial Markets the main drivers are Electronics, Sealing and the North American Business.
- Q2'22 Gross margin: -1.5%pts behind PY, good volumes and additional price increases in place with a certain time lag to realize full impact offset by inflation and energy cost pressure.
- Q2'22 SG&A margin: decrease vs. PY by 0.2%pts partly driven by volume growth and selected initiatives to improve customer focus, with ongoing cost control.
- Q2'22 Management Adj. EBITDA margin showing a solid performance at 40.5% with -1.9%pts vs PY.




### **Investor Call Q2 2022** YTD 33,8% Operational Cash Conversion (before Transaction and PPA effects)

Quarterly Cash Flow for Debt Repayment (EURm)



#### YTD Cash Flow for Debt Repayment (EURm)




#### **Reported Total CF to Cash Flow for Debt Repayment**

in EURm	Q1 21	Q2 21	Q3 21	Q4 21	FY 21	Q1 22	Q2 22	Q3 22	Q4 22	YTD 2
Cash flow for debt repayment	7	<b>4</b> 4	31	20	101	-10	-18			
+ RCF drawdown / (repayment)	0	) C	0	0	0	0	0			
+ Ancillary drawdown / (repayment) / syndicated loan	0	) C	0	0	0	238	0			2
- Acquisition / Transaction	-50	) C	1	0	-49	-1834	0			-18
- Cash received from contribution to capital reserve	0	C	0	0	0	1608	0			16
- Bond issuance / repurchase	0	) C	0	0	0	42	0			
- SHL cash received / repayment (principal + interest)	0	C	0	-5	-5	-293	0			-2
Total CF (as reported)	-44	44	32	15	47	-250	-18			-2




### Investor Call Q2 2022 Net Capex Development



- Capex continues to be managed tightly with focus on growth investments in key end markets.
- Key Projects ensure long term capacity increase projects in Medical markets, necessary maintenance activities and selected Industrial projects, digitalization and ESG projects.
- Q2 on prior year level, expected to accelerate over the next quarters to ensure that strong increase in order intake.
- Continued monitoring in the light of possible Covid- or Recession issues



### Investor Call Q2 2022 Net Debt And Leverage Ratio



In EURm	June 30, 2021	June 30, 2022
Senior Debt	1,194.4	1,480.0
Bonds	406.0	465.0
Other	4.5	0.7
Revolver	0.0	0.0
Accrued Interests	10.9	10.2
Gross Debt	1,615.8	1,955.9
- Cash	-244.1	-23.4
Total Net Debt	1,371.7	1,932.6
LTM Adj. EBITDA	249.7	267.8
Leverage Ratio	5.5x	7.2x
Senior Net Debt Lev. Ratio	3.8x	5.4x
Net Senior Debt (SFA)	954.8	- *
Cons. Pro Forma EBITDA (SFA)	257.0	- *
Leverage ratio (SFA)	3.7x	_ *

\* No Compliance Certificate required



# **Investor Call** Q2 2022



> Plochingen, September 28, 2022 – public-side information only

• CEO – Dr. Hadi Saleh

